Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors

Azad, Fatemeh Mirzadeh; Naeli, Parisa; Malakootian, Mahshid; Baradaran, Azar; Tavallaei, Mahmood; Ghanei, Mostafa; Mowla, Seyed Javad

doi:10.1016/j.gene.2015.11.040

Cited by 21 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our results, miR-135b was upregulated in highly invasive NSCLC cells [27] and miR-134 was upregulated in lung tumors, though no correlation was found between miR-134 and clinicopathological characteristics or survival [28]. …”

Section: Discussionsupporting

confidence: 85%

YKT6 expression, exosome release, and survival in non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

BackgroundCancer-derived exosomes are involved in metastasis. YKT6 is a SNARE protein that participates in the regulation of exosome production and release, but its role in non-small cell lung cancer (NSCLC) has not been examined.Materials and MethodsUltracentrifugation-purified exosomes from the A549 cell line were studied by CRYO-TEM, nanoparticle tracking analysis and western blot (TSG101 marker). YKT6 was inhibited using a DsiRNA and selected pre-microRNAs. MicroRNAs targeting YKT6 were validated by Renilla/Luciferase assay and western blot. YKT6 expression and its prognostic impact were analyzed in 98 tissue specimens from resected NSCLC patients.ResultsMembranous nanosized vesicles (mode size: 128nm) with TSG101 protein were purified from A549 cells. YKT6 inhibition reduced exosome release by 80.9%. We validated miR-134 and miR-135b as miRNAs targeting YKT6, and transfection with the pre-miRNAs also produced a significant reduction in exosome release. The analysis of YKT6 in tumor samples showed that patients with high levels had shorter disease-free and overall survival.ConclusionsYKT6 is a key molecule in the regulation of exosome release in lung cancer cells and is in turn precisely regulated by miR-134 and miR-135b. Moreover, YKT6 levels impact prognosis of resected NSCLC patients.

show abstract

Section: Discussionsupporting

confidence: 85%

YKT6 expression, exosome release, and survival in non-small cell lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…First, miR-134 was dysregulated in various tumors and carcinomas, whereas it may present different expression in identical cancer. For instance, miR-134 was elevated in two studies about lung cancer,88, 110 whereas it was decreased in other references about lung cancer 34, 35, 69, 90. Similarly, it was found to downregulate in HNSCC, while it was also upregulated in another study of HNSCC 64, 83.…”

Section: Main Textmentioning

confidence: 91%

“…It seems to be a cancer suppressor because it repressed cancer cell proliferation and xenograft development and boosted tumor cell apoptosis, migration, and metastasis as well as benefited patient survival and prognosis in major papers. However, it also acted as a devil for it induced tumorigenesis, cancer cell growth, prohibited apoptosis, enhanced metastasis, as well as led to poor prognosis in some investigations 64, 88, 110…”

Section: Main Textmentioning

confidence: 99%

miR-134: A Human Cancer Suppressor?

Pan

Zhang

Sun

et al. 2017

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small noncoding RNAs approximately 20–25 nt in length, which play crucial roles through directly binding to corresponding 3′ UTR of targeted mRNAs. It has been reported that miRNAs are involved in numerous of diseases, including cancers. Recently, miR-134 has been identified to dysregulate in handles of human cancers, such as lung cancer, glioma, breast cancer, colorectal cancer, and so on. Increasing evidence indicates that miR-134 is essential for human carcinoma and participates in tumor cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. Nevertheless, its roles in human cancer are still ambiguous, and its mechanisms are sophisticated as well, referring to a variety of targets and signal pathways, such as STAT5B, KRAS, MAPK/ERK signal pathway, Notch pathway, etc. Herein, we review the crucial roles of miR-134 in scores of human cancers via analyzing latest investigations, which might provide evidence for cancer diagnose, treatment, prognosis, or further investigations.

show abstract

“…miR-134 has been indicated to be differentially regulated in lung cancer and other types of cancer (including gastric cancer, breast cancer and oral cancer), with certain studies reporting increased expression in lung cancer ( 66 , 67 ), while other studies observed that it was downregulated ( 68 , 69 ). miR-134 may function to either promote or suppress tumor progression ( 69 , 70 ), highlighting complex mechanisms warranting further investigation.…”

Section: Discussionmentioning

confidence: 99%

Identification of key differentially expressed mRNAs and microRNAs in non‑small cell lung cancer using bioinformatics analysis

Wang

Pan

2020

Exp Ther Med

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is a leading cause of mortality worldwide. However, the pathogenesis of NSCLC remains to be fully elucidated. Therefore, the present study aimed to explore the differential expression of mRNAs and microRNAs (miRNAs/miRs) in NSCLC and to determine how these RNA molecules interact with one another to affect disease progression. Differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were identified from the GSE18842, GSE32863 and GSE29250 datasets downloaded from the Gene Expression Omnibus (GEO database). Functional and pathway enrichment analysis were performed based on Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. STRING, Cytoscape and MCODE were applied to construct a protein-protein interaction (PPI) network and to screen hub genes. The interactions between miRNAs and mRNAs were predicted using miRWalk 3.0 and a miRNA-mRNA regulatory network was constructed. The prognostic value of the identified hub genes was then evaluated via Kaplan-Meier survival analyses using datasets from The Cancer Genome Atlas. A total of 782 DEGs and 46 DEMs were identified from the 3 GEO datasets. The enriched pathways and functions of the DEGs and target genes of the DEMs included osteoclast differentiation, cell adhesion, response to a drug, plasma membrane, extracellular exosome and protein binding. A subnetwork composed of 11 genes was extracted from the PPI network and the genes in this subnetwork were mainly involved in the cell cycle, cell division and DNA replication. A miRNA-gene regulatory network was constructed with 247 miRNA-gene pairs based on 6 DEMs and 210 DEGs. Kaplan-Meier survival analysis indicated that the expression of ubiquitin E2 ligase C, cell division cycle protein 20, DNA topoisomerase IIα, aurora kinase A and B, cyclin B2, maternal embryonic leucine zipper kinase, slit guidance ligand 3, phosphoglucomutase 5, endomucin, cysteine dioxygenase type 1, dihydropyrimidinase-like 2, miR-130b, miR-1181 and miR-127 was significantly associated with overall survival of patients with lung adenocarcinoma. In the present study, a miRNA-mRNA regulatory network in NSCLC was established, which may provide future avenues for scientific exploration and therapeutic targeting of NSCLC.

show abstract

Two lung development-related microRNAs, miR-134 and miR-187, are differentially expressed in lung tumors

Cited by 21 publications

References 41 publications

YKT6 expression, exosome release, and survival in non-small cell lung cancer

YKT6 expression, exosome release, and survival in non-small cell lung cancer

miR-134: A Human Cancer Suppressor?

Identification of key differentially expressed mRNAs and microRNAs in non‑small cell lung cancer using bioinformatics analysis

Contact Info

Product

Resources

About